Jara Joedicke is an immunologist with a passion for the development of novel cancer therapies.
She has over 10 years molecular biology experience in both academia and industry.
Throughout her career she has managed a variety of employees from students and postdoctoral
researchers to technical staff. Her aim is to bring novel cell and gene therapies rapidly
from the bench to the clinic, especially those utilizing CAR T cells.
Eric Alonzo
Strategy Lead, Oncology, Analytical Development & CMC Lead, bbT369 Program, bluebird
bio
Dr Alonzo serves as the CMC Lead for the bbT369, a pre-clinical program for the treatment
of B-NHL and Analytical Strategy Lead for the Oncology Divsion at bluebird bio. Previously,
Dr Alonzo led the Oncology Characterization Team where he focused on the development
of analytical and characterization assays for CAR T/TCR cell programs. Prior to bluebird bio,
Dr Alonzo lead efforts developing T-cell-based therapies at Agenus, and previous to his work
at Agenus, he was a postdoctoral fellow at Harvard Medical School studying transcriptional
and epigenetic dysregulation that leads to the development of T-cell acute lymphoblastic
leukemia. Dr Alonzo received his PhD from the Cancer Biology Program at the Memorial
Sloan-Kettering Cancer Center.
Marsilius Mues
R&D Group Leader at Miltenyi Biotec
Dr Mues joined the R&D Department of Miltenyi Biotec in 2017. In his current role he leads
the interdisciplinary research and development in the field of immuno-oncology and cellular
therapeutics, with a focus on CAR T cell engineering for personalized immunotherapy.
He oversees the establishment of multiparametric immune assays for functional characterization
of engineered T cells, along with automated data acquisition and analysis tools for
translational research, cell therapy manufacturing, and patient immune monitoring during
clinical trials. He performed his PhD studies at the Max Planck Institute of Neurobiology on T
cell signaling during autoimmune disease and completed his postdoctoral research at UCSF
where he focused on novel combinatorial therapies using high-complexity lentiviral shRNA
& CRISPR/Cas9 libraries for T-cell leukemia.
